Search Medical Condition
Please enter condition
Please choose location from dropdown

Moenchengladbach, Germany Clinical Trials

A listing of Moenchengladbach, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (49) clinical trials

OPTIMAL>60 / DR. CHOP Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Primary objective of study: "OPTIMAL>60 Less Favourable" Patients with less favourable prognosis: To test whether progression-free survival (PFS) can be improved by substituting conventional by liposomal vincristine; To test whether PFS can be improved by 12 optimised applications instead of 8 2-week applications of rituximab. "OPTIMAL>60 Favourable": Patients with favourable ...

Phase

0.0 miles

Learn More »

Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.

Background Prevailing curative intended therapeutic strategies combine radical resection of the tumor mass with a safety margin followed by radiation of the original tumor site and adjacent locoregional lymphatic drainage areas. To date selection of the individual therapeutic pattern is essentially guided by pre- and post-therapeutic TNM staging parameters. Exceptionally ...

Phase

0.0 miles

Learn More »

International Registry on the Use of the CytoSorb Adsorber

The aim of this registry is to record the use of CytoSorb under real life conditions in as many cases as possible (preferably all or, at least, in a representative sample). All CytoSorb applications in different clinical settings and in all patients who are treated with this technology in Germany, ...

Phase N/A

0.0 miles

Learn More »

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Phase

0.0 miles

Learn More »

A Study of ASP8302 in Participants With Underactive Bladder

The study will comprise a screening visit, followed by a treatment period and a 2-week follow-up period, in total 8 weeks. Participants will visit the clinic at screening (visit 1) and every 2 weeks (visit 2, 3, 4, and 5). During the course of the study assessments will be performed ...

Phase

0.0 miles

Learn More »

IDOMENEO - Is Treatment Reality in Vascular Medicine Evidence-based and Follows Guideline Recommendations? A Project for Quality Development Exemplified by Peripheral Arterial Disease (PAD)

The prevalence of peripheral arterial disease (PAD) and the proportion of endovascular procedures for treatment are increasing worldwide. For many cases of treatment or procedures no randomized controlled trials (RCT) or results from meta-analyses are so far available. The decision for treatment and selection of procedure is therefore not uncommonly ...

Phase N/A

0.0 miles

Learn More »

Study of a Quadrivalent Meningococcal Conjugate Vaccine Compared With Two Meningococcal Reference Vaccines in Europeans Toddlers

Study duration per participant is approximately 30 days including: 1 day of screening and vaccination, a phone call and a safety-follow up/end of study visit at Day 8 and Day 30 after vaccine administration, respectively. Safety assessment includes solicited reactions within 7 days after vaccination, unsolicited adverse events (AEs) up ...

Phase

0.98 miles

Learn More »

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.

Phase

1.11 miles

Learn More »

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

Around 40% of moderate to severe psoriasis patients are affected by concomitant metabolic syndrome, making it one of the clinically most relevant comorbidities. Psoriasis as well as the metabolic syndrome are both characterized by a state of low-grade systemic inflammation (e.g. in the skin, joints, adipose tissue, liver or vascular ...

Phase

1.11 miles

Learn More »